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The current research aimed to formulate and optimize testosterone enanthate-loaded solid lipid 36 
nanoparticles (TE-SLNs) for the enhanced TE transdermal delivery. To this end, TE-SLNs were 37 
prepared using ultrasound-assisted emulsification technique and their properties and permeation 38 
across the excised rat skin were investigated. Evaluation of lipid type as well as the ratio and 39 
contents of surfactant mixtures resulted in a polydispersity index, particle size, drug loading, drug 40 
encapsulation efficiency, and zeta potential of 0.317± 0.006, 87.66± 1.52 nm, 21.61± 0.45 %, 41 
44.71± 1.14 % and -23.06± 0.50 mV, respectively. ATR-FTIR spectra of TE-SLNs exhibited the 42 
prominent functional groups of TE in the formulations, indicating a well-dispersion of TE in the 43 
lipid matrix without any chemical interaction with other components of the formulation. 44 
Differential scanning calorimetry (DSC) demonstrated that TE in SLNs is in an amorphous state. 45 
Transmission electron microscopy (TEM) confirmed that the prepared TE-SLNs have a stable size 46 
and maintained their sphericity. The results of TE permeation across the excised rat skin from 47 
SLNs displayed cumulative amounts of 110.61±17.7 µg/cm2, which is 3.2 fold improvement in 48 
TE permeation in comparison with the testosterone enanthate solution in oleic acid (p< 0.05). 49 
Furthermore, no cellular toxicity was observed for the nanoparticles. The results showed that the 50 
prepared TE-SLNs can be applied as the potential carriers for transdermal delivery of testosterone 51 
enanthate. 52 
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Introduction  59 
Anabolic steroids are a class of compounds involving any medicine or hormonal substance and 60 
have a chemical and pharmacological relation with testosterone enanthate. It also would stimulate 61 
tissue growth [1]. The first class of anabolic steroids is testosterone esters such as testosterone 62 
enanthate (TE), testosterone cypionate, and testosterone undecanoate. In addition, TE and 63 
testosterone cypionate are the injectable forms of testosterone esters. However, TE is absorbed 64 
slowly, and the peak serum concentration for this substance is about 72 h after its intramuscular 65 
(IM) injection [2]. Some researchers indicated that since IM injection of testosterone esters results 66 
in local irritation; therefore, the absorption rate might be affected by the local irritation of the tissue 67 
[2, 3]. Nevertheless, different research demonstrated the benefits of TE replacement therapy [4]. 68 
A study performed in the field revealed that achieving a physiological TE pattern (circadian 69 
rhythm) and physiological levels of metabolites (dihydrotestosterone and estradiol) strictly 70 
depends on the administration route [2]. Moreover, studies on the administration routes illustrated 71 
that the transdermal approach provides some advantages over the oral route or hypodermic 72 
injections. Since testosterone enanthate is largely metabolized in the gastrointestinal (GI) and the 73 
liver; hence, the oral route needs a high dose and this can cause more and serious side effects in 74 
comparison to the transdermal approach [5]. Thus, it would be beneficial to patients to explore a 75 
formulation for TE that can provide a systematic release and increase patient compatibility such 76 
as the transdermal delivery route. It has been shown that the transdermal route can offer prolonged 77 
drug release and increase patient compliance in comparison with the injection and oral drug 78 
delivery methods [6].  Due to having many advantages and fewer drawbacks for transdermal 79 
delivery compared to other routes, researchers have been tried to develop a reliable delivery system 80 




as a scrotal patch in the late 1980s [8]. According to some researchers, non-scrotal patches have 82 
appeared in the late 1990s, and these patches, due to a low level of 5-α reductase in non-scrotal 83 
skin, resulted in physiological dihydrotestosterone serum level [9]. It has also been pointed out by 84 
researchers, TE patches have some disadvantages, including skin irritation [10], adhesion 85 
problems, limited dosing flexibility, and elevated manufacturing cost [2]. It seems it is possible to 86 
overcome these limitations by introducing advanced lipid nanoparticles (NPs), such as solid lipid 87 
nanoparticles (SLNs). Besides, NPs can be employed for improving the solubility of poorly soluble 88 
drugs [11, 12]. It should be noted that TE, which is the model drug in the present research, is also 89 
water-insoluble (<0.5μg/mL) with a log P of 3.58. Thus, researchers stated that loading TE in 90 
SLNs could be a strategy for improving its solubility. In this context, they developed SLNs as an 91 
option for carrier systems [13] so that these SLNs have been greatly considered as one of the 92 
innovative colloidal drug carriers to be topically applied [14]. It is believed that SLNs are able to 93 
keep useful features of other popular colloidal carriers. Moreover, they do not suffer from any 94 
drawbacks concerning physicochemical storage stability, loading capacity (LC), toxicity, 95 
feasibility, target-oriented releasing properties, and production scale [15]. In addition, some 96 
researchers referred to the SLNs characteristics that can lead to skin hydration and increase drug 97 
absorption [16, 17]. Furthermore, researchers have applied SLNs to enhance the skin/dermal 98 
uptake of multiple medicines [18-21], which confirms that SLNs have the capability to be served 99 
as a topical delivery system for TE. 100 
Although the impact of surfactants mixture on the efficiency of solid lipid nanoparticles carrier 101 
has been recently reported [22, 23], there is no comprehensive study to investigate a simultaneous 102 




for the enhanced transdermal delivery. The properties, toxicity and permeability studies of the 104 
prepared TE-SLNs were also evaluated.  105 
 106 
2. Materials and methods 107 
2.1. Materials 108 
Testosterone enanthate was purchased from Caspian Tamin Pharmaceutical Company, (Guilan, 109 
Rasht, Iran). Stearic acid (SA), palmitic acid (PA), glycerol monostearate (GMS), oleic acid (OA), 110 
and tween 80 and span 80, HPLC grade acetonitrile and absolute ethanol were obtained from 111 
Merck, Germany. In addition, beeswax (BW) was purchased from John’s laboratory (John’s 112 
laboratory chemicals: India).  A Human power 2 system (human Co., Korea) has been used to treat 113 
the distilled water. DMSO and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 114 
(MTT) were obtained from Sigma (St. Louis, MO, USA).   115 
 116 
2.2. Preparation of TE-SLNs 117 
SLNs formulations have been performed by modification of ultrasound-assisted emulsification 118 
methods reported in the literature [24, 25]. Typically, a mixture of beeswax and TE was heated to 119 
75 °C and stirred for 20 min to achieve a homogenous oil phase. Then, a mixture of span 80 and 120 
tween 80 as a surfactant mixture was dissolved in double distilled water to obtain a surfactant 121 
aqueous phase. Both phases (aqueous and oil phases) were separately heated to 75 ºC. After 122 
reaching the required temperature, the aqueous phase was added onto the oil phase drop-wise under 123 
the stirring condition to produce an oil-in-water emulsion. Then, a probe sonicator was applied to 124 
sonicate the mixture (Bandelin; 3100; Germany, with an amplitude of 20% for 10 minutes). After 125 
sonication, the nanoemulsion was maintained in the ice bath for 10 min by stirring at 300 rpm to 126 




2.3. Description of the prepared TE-SLNs 128 
2.3.1. Size of the nanoparticle, polydispersity index, and zeta potential evaluation 129 
Dynamic light scattering (DLS) with Nano ZS zetasizer (Malvern Instruments, Worcestershire, 130 
UK) was employed to measure the particle size mean diameter, polydispersity index, and zeta 131 
potential at 25°C with an angle of 90° [26]. It should be noted that all measurements have been 132 
carried out in triplicates. 133 
 134 
2.3.2. Evaluation of drug loading (DL) encapsulation efficiency (EE)  135 
2.0 mL of freshly prepared TE-SLNs were subjected to centrifugation at 54957 ×g (Sigma; 136 
Germany) for 120 min at 4°C to separate the lipid and aqueous phases.  After separation of the 137 
loaded TE from dispersion the supernatant was passed through a syringe filter (0.22μm), and the 138 
amount of free TE in the supernatant was measured via HPLC (Knauer, Berlin, Germany) 139 
consisted of the XDB C18 column (5 μm; 4.6×250 mm; Germany) [27]. The detection limit (DL) 140 
and quantification limit (QL) were determined using the standard deviation (SD) and the slope (S) 141 
of the calibration curve according to the International Conference on Harmonization (ICH)  [28] 142 
by 3.3 SD/S and 10 SD/S to DL and QL respectively [29]. The mobile phase was a mixture of 143 
acetonitrile/water (90:10, v/v), the flow rate was set up at 1 ml/min and UV detection wavelength 144 
was 254 nm. The specified working range with DL value of 0.81 µg/ml and QL value of 2.45 145 
µg/ml, was kept in the concentration range of 1-100 µg/ml. Drug encapsulation efficiency (EE%) 146 
and drug loading (DL%) were obtained using Eqs. 1 and 2. [30]  147 
EE (%)= (Total amount of Drug-Free drug/Total amount of drug) *100 (Eq.1.) 148 
DL (%)= (Total amount of Drug-Free drug/Total amount of lipid) *100 (Eq.2.) 149 




Cary 630 FTIR spectrophotometer (Agilent Technologies Inc., CA, USA) with a diamond ATR 151 
(Attenuated Total Reflectance) was used to study the TE–excipient interactions. Then, TE, BW, 152 
span 80, tween 80, and their physical mixtures were examined by ATR-FTIR. According to the 153 
above procedure, the spectra were recorded by placing a low amount of each homogeneous sample 154 
on the slit and the samples were scanned from 400 to 4000 cm-1 and 2 cm-1 of resolution. 155 
 156 
2.3.4. Diff erential scanning calorimetry (DSC) 157 
DSC was used to analyze the thermal behavior of the solid lipid, pure drug, and drug-loaded SLNs. 158 
Before the heating process, about 4 mg of the samples were weighed in the hermetic crimped 159 
aluminum pan, preserved at 30 °C for thirteen minutes. The samples were heated up to 300 °C at 160 
a scanning rate of 20 °C/min under a nitrogen atmosphere. Pyris 6, (Perkin Elmer, USA) was used 161 
to evaluate the DSC traces. Indium (melting transition = 429.75 K) was used as the standard to 162 
calibrate the DSC. 163 
 164 
2.3.5. Powder X-ray diffractometer (PXRD) analyses 165 
D8 Advance X-ray diff ractometer (Bruker-binary V2: Germany) (40k; 30mA) was used to obtain 166 
the patterns of the powder X-ray diffraction (XRD) for identifying any alterations in the crystal 167 
lattice of the substances in the SLNs. Moreover, analysis of the crystalline properties of TE, BW, 168 
and freeze-dried TE-SLNs powder was performed by exposing them to Cu Kα radiation at a 169 
wavelength of 1.5406 Å. Then, the samples were scanned from 5.000° to 70.000°, 2Ɵ at a step 170 
size of 0.040° and step time of 1 s [26]. 171 
 172 




TEM microscope (Philips CM 120 KV, Amsterdam: The Netherlands) was used to examine the 174 
TE-SLNs morphology. To this end, some drops of TE-SLNs was placed on carbon-coated copper 175 
grids. Then, a 2% (v/v) phosphotungstic acid solution was prepared to negatively stain the 176 
nanoparticles for 30 seconds. Finally, the solvent has been let to be dried overnight at room 177 
temperature, and TEM visualization has been administered [31].  178 
 179 
2.4. Cell viability assay  180 
The human gingival fibroblast cells (HGF3-PI53) were achieved from the National Cell Bank of 181 
Iran (Pasteur Institute of Iran; Tehran: Iran) and were seeded (2×104 cells/well) in order to grow 182 
in a 96-well plate. In addition, blank SLNs and distinct concentrations of TE-SLNs were added to 183 
the cells after 24 h. All conditions were adjusted three times. Moreover, the rapid growth and 184 
vitality of the cells were measured using 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium 185 
bromide (MTT) assay. Furthermore, a reaction was found between the MTT agent and its 186 
tetrazolium ring for producing blue formazan crystals in the viable cells. After passing 24 and 48 187 
hours, the supernatant was eliminated from each well. Then, phosphate-buffered saline (PBS) was 188 
used to wash each cell 3 times for removing nonviable cells. Afterwards, 100 µL of fresh media 189 
with 0.5 mg/mL of MTT solution was added into the wells. Then, incubation of the cells was done 190 
at 37 °C for four hours in order to form the formazan crystal. Consequently, the supernatant was 191 
discarded after incubation. Next, 200 µL of dimethyl sulfoxide was added into the wells to dissolve 192 
formazan crystals under continuous pipetting. In addition, a microplate reader (Awareness, USA) 193 
was used to measure optical density through the spectrophotometric method at a wavelength of 194 
570 nm. Finally, Eq. 2 was employed to calculate the living cells percentage: 195 
 196 





According to the results, the blank had only the media while the control had the cells with media. 199 
It should be noted that the cells with no TE-SLNs were employed as a reference for 100% cell 200 
survival. However, the average of the results from 3 different experiments was achieved, and the 201 
t-test and Spearman’s correlation coefficient were used to do statistical analyses. Finally, a p-value 202 
of <0.05 was regarded as statistically significant [32]. 203 
 204 
2.5. In-vitro examination of the skin permeation  205 
This research was designed according to the Ethical Guidelines for Investigations in Laboratory 206 
Animals. The Ethics Review Committee for Animal Experimentation of Mazandaran University 207 
of Medical Sciences with the ethical code of IR.MAZUMS.REC.96.2975 confirmed the research. 208 
Moreover, in vitro skin absorption assessment was conducted on the Franz diffusion cell with an 209 
efficient diffusion area of 3.8 cm². For this purpose, the abdominal area of the male Wistar rats 210 
(with a weigh of 120–150g) was shaved. Then, the rats were anaesthetized with 13 mg xylazine/kg 211 
and87 mg ketamine/kg of body weight. After 48 h, the rats were sacrificed with chloroform 212 
inhalation. Afterwards, abdominal skins were removed by surgery. Next, the skin was precisely 213 
cleaned from the adhered sub-cutaneous fats, and placed in a normal saline solution for 24 hours 214 
before diff usion experiments. The skins were incised into circular segments and inserted in a Franz 215 
diffusion cell between receptor and donor compartments in a way that the stratum corneum side 216 
was faced with the donor chamber and the dermal side was faced with the receptor chamber. The 217 
receptor section had 70% v/v absolute alcohol/water at 32 °C as a suitable solvent system [33]. 218 
Then, 4 mL of nanoemulsion formulation or control formulation was added into the donor section. 219 




water evaporation. After 2, 4, 6, 8, 10, 12, and 24 h, the samples were taken and replaced with 221 
absolute ethanol/water (70:30). Then, the samples were analyzed with HPLC method. Afterwards, 222 
the skins were removed, and deionized water was used to wash them three times followed by 223 
drying the samples to measure the sedimented TE in the skin. The removed skins were incised into 224 
small pieces and transferred to water tubes where they were soaked for 24h, then they were 225 
sonicated for an hour using a bath sonicator. It should be noted that for TE evaluation, the 226 
supernatants were filtered by a filter paper, passed another time, filtrated through a syringe filter 227 
(0.22 μm), and subsequently, HPLC was used to quantify the samples [26, 34]. 228 
 229 
2.6. Statistical analysis  230 
All data were analyzed with SPSS2021 and GraphPad Prism 5.0 (version 8.0.0.0; GraphPad 231 
Software. Inc., San Diego, California, USA) software. The data were expressed as Mean± SD. 232 
Moreover, significant differences between two and more groups were analyzed via Student’s t-test 233 
and ANOVA, respectively. In addition, P greater than 0.05 was regarded as a statistically 234 
significant value in all cases. 235 
 236 
3. Results and discussion 237 
3.1. Optimizing TE-SLNs 238 
In the present research, TE-SLNs have been procured via homogenization using the ultrasonic 239 
process. All these emulsion systems contained water, lipid, TE, and surfactant or surfactants 240 
mixture. It has been found that the relation between interfacial characteristics and emulsion 241 
stability is important for the development of a product with high stability [35]. Therefore, 242 




electrical obstacles [36, 37]. Moreover, the use of surfactants mixture would not only improve the 244 
stability of solid lipid nanoparticles structure and particles amorphous but also reduce their particle 245 
size due to its synergy [38, 39]. According to some studies, efficient hydrophilic-lipophilic balance 246 
(HLB) value is one of the most effective parameters for an appropriate surfactant system. Thus, 247 
the surfactants chemical structure and characteristics should be considered [40-42]. Notably, many 248 
nonionic surfactants such as sorbitan fatty acid esters (spans) and the polyoxyethylene sorbitan 249 
fatty acid esters (tweens) have found potential pharmaceutical applications [43].  250 
To achieve a stable drug-loaded SLNs, in the current research, binary mixtures of span 80 (HLB: 251 
4.3): tween 80 (HLB: 15) at different amounts (1 to 3 g) and ratios (2:1, 1:1, 1:2, and 0:1) were 252 
used to obtain different HLB values (7.8, 9.6, 11.4, and 15, respectively) [23]. Various surfactant 253 
mixtures (based on the above-mentioned HLBs) with different lipids such as stearic acid, palmitic 254 
acid, glyceryl monostearate, and beeswax have been investigated while the amount of TE has been 255 
kept constant. Moreover, suitable solid lipid has been selected based on the stability and 256 
nanoparticles characteristics such as polydispersity index, size of the nanoparticles, and zeta 257 
potential parameters (data are not shown) [44]. The results showed that TE-SLNs containing SA 258 
and PA are not stable. However, the main reason for the instability of the structure of the 259 
nanoparticle in both low and high concentrations of lipids and constant amount of surfactants (in 260 
every HLB) could be related to the aggregation of particles which was evident from the appearance 261 
of the samples. On the other hand, the high chain length of stearic acid and palmitic acid could be 262 
another restraint for setting stable TE-SLNs [45]. It has been also found that GMS and BW lipids 263 
led to better results, but TE-SLNs instability and PDI have been higher in GMS-containing SLNs 264 
compared to the BW-based lipid nanoparticles. Therefore, among various lipids (glycerol 265 




higher solubility of TE in beeswax, it was selected for further examinations. The results revealed 267 
that more than 1 g of BW caused physical instability such as creaming, coalescence, phase 268 
separation, and precipitation of SLNs. The results for the surfactant system showed that the optimal 269 
values of surfactant mixtures ≤ 3 g led to a transparent dispersion while higher amounts of 270 
surfactants made the dispersion opaque, which could be due to the particles aggregation.  271 
 272 
3.2. Physical properties of TE-SLNs 273 
3.2.1 The effect of surfactants mixture contents on TE-SLNs properties  274 
According to the studies, the selection of proper amounts of surfactants has a major effect on the 275 
quality of the SLN dispersion [15]. Other studies also demonstrated that span 80 is an inexpensive 276 
and molecularly heterogeneous mixture of mono-, di-, tri-, and tetra esters with primary diesters 277 
and oleoyl (cis-9octadecenoyl) chains [46, 47]. Tween 80 is oleic acid esterified with 278 
polyethoxylated sorbitan, with 20  subunits of ethylene oxide in each molecule which made it 279 
hydrophilic [48]. The mixtures of these nonionic surfactants with different quantities (1, 2 and 3 280 
g) have been used to prepare solid lipid nanoparticles. Based on the results in Table 1 (F1 to F12), 281 
it could be concluded that the amounts of surfactants mixture significantly affected the SLNs 282 
properties such as the mean particle size, polydispersity index, zeta potential, and EE parameters. 283 
In addition, some researchers indicated that different contents of surfactant mixtures (composing 284 
of HLBs of 7.8, 9.6, 11.4, and 15) have been screened, while the amounts of TE and BW have 285 
been kept constant. Furthermore, the characteristics of the nanoparticles for the investigated 286 
formulations indicated that the SLNs containing the least amount of surfactants mixture (1 g) have 287 
poor stability (F1, F4, F7, F10, and PDI> 0.5) with a high creaming rate [49]. Nonetheless, other 288 




increased unification of particles during homogenization which could be caused by a significant 290 
increase in the surface area [15, 50].  291 
It was also found that increasing the quantity of surfactants mixture from 1 g (F1, F4, F7, and F10) 292 
to 2 g (F2, F5, F8, and F11) or 3 g (F3, F6, F9, and F12) in all HLBs significantly reduced the 293 
mean particle size and polydispersity index, while the zeta potential increased (P<0.0001) and 294 
resulted in better TE-SLNs stability.  As it could be predicted, increasing the surfactant 295 
concentration leads to lower the surface tension, and makes the partition of particles easier 296 
throughout the preparation [15, 39] and reduces the particle size. Additionally, further steric 297 
stabilization of particles can be provided by tween 80 and span 80. The interpenetration of existing 298 
long polyethylene chains in the mixture of surfactants restricts the particle freedom and inhibits 299 
them from connecting to each other [15]. As reported in the previous study [51], the type of lipid 300 
directly affects the zeta potential outcomes. The high zeta potential and stability of the selected 301 
formulations could confirm that BW is an appropriate lipid in this research. Further scrutiny of the 302 
data in Table 1 demonstrates that increasing the amount of the surfactants mixture from 2 g (F2, 303 
F5, F8, and F11) to 3 g (F3, F6, F9, and F12) in all HLBs does not make any significant difference 304 
in the SLNs properties, including zeta potential, the mean particle size, and polydispersity index 305 
(P> 0.05); however, TE encapsulation efficiency significantly decreased (P<0.0001). This could 306 
be attributed to the enhanced solubility of TE in the aqueous phase with the increase in the amount 307 
of the surfactants mixture [52, 53]. According to these results, the optimum amount of surfactants 308 
mixture has been found to be 2 g in all different HLBs with constant amounts of TE (0.5 g) and 309 
BW (1 g). 310 
 311 




As stated by researchers, the impact of HLBs on the polydispersity index, the mean size of the TE-313 
SLNs particles, zeta potential, and EE can be evaluated by comparing formulations with constant 314 
amounts of TE (0.5 g), BW (1 g), and surfactants mixtures (2 g, different compositions of span 80 315 
and tween 80) shown in Table 1 (F2, F5, F8, and F11). Findings revealed that the ratio of span 316 
80/tween 80 >1 gives the highest average particle size (342.66± 0.57 nm) and PDI (0.649± 0.046) 317 
as well as the least zeta potential (-10.83±1.10 mV) and encapsulated TE (1.95± 0.36). These 318 
observations could be as a result of the particle agglomeration and difference between HLBs of F2 319 
(HLB 7.8) and BW (HLB 12). Moreover, the ratios of span 80/tween 80 ≤ 1 led to a significant 320 
decrease in the particle size and PDI, and an increase in the zeta potential and EE % (comparing 321 
F2 with F5, F8, and F11). However, using the tween 80 alone as an emulsifier (F11) was not 322 
adequate for stabilizing TE-SLNs and gave relatively low EE value (19.17± 1.54 %), average 323 
particle size (124.33± 2.51 nm), PDI (0.463± 0.008) and zeta potential (-18.5± 2.3 mV). These 324 
results could be related to the HLB value of tween 80, which is not suitable for emulsifying BW 325 
with an HLB value of 12. However, a combination of span 80: tween 80 with the ratio of 1:2 and 326 
HLB of 11.4 (F8) led to the reduction of the particle size (87.66± 1.52 nm), PDI (0.317± 0.006), 327 
and an increase of the zeta potential (-23.06± 0.50 mV) and EE (44.71± 1.14 %). Again, such a 328 
condition could be attributed to the HLB values of surfactants mixtures (HLB 11.4) and BW (HLB 329 
12), which are very close values, and result in the TE-SLNs appropriate properties. It should be 330 
noted that structural differences between span 80 and tween 80; that is, the lipophilicity of span 80 331 
and hydrophilicity of tween 80 provided the necessary stabilization in the emulsion system, and 332 
generated low particle size and PDI as well as high zeta potential and encapsulation efficiency 333 
[43]. In addition, researchers confirmed the stability of formulation F8 by measuring the particle 334 




size of TE-SLNs (data are not shown). According to the study conducted in the field, since it is 336 
known that the absolute large value of zeta potential is required for dispersion stability [54], the 337 
range of zeta potential measured for SLNs with span 80: tween 80 mixture is not high enough to 338 
generate the electrical field around the particles. This could suggest that steric and electrostatic 339 
stabilization can prevent the aggregation of nanoparticles [39]. 340 
As the maximum encapsulation efficiency (44.71± 1.14 %) has been acquired for F8, all the 341 
characterization studies have been conducted for this formulation. 342 
 343 
3.2.1. ATR-FTIR analysis 344 
The ATR-FTIR technique has been used to explore the probable physicochemical interaction 345 
among the chemicals used to generate SLNs. Fig.1 shows the ATR-FTIR spectra of beeswax, span 346 
80, tween 80, TE, and TE-SLNs. The ATR-FTIR spectra of beeswax [55], span 80 [56], and tween 347 
80 [57] have been compatible with their structures. The TE spectrum exhibited characteristic bands 348 
consistent with the published data [58]. Moreover, the characteristic peaks of testosterone 349 
enanthate could be observed in the ATR-FTIR spectrum of TE-SLNs. The absorption peaks of 350 
ketone C = O stretching, ester C = O stretching and conjugated C = C stretching at respectively 351 
about 1674 cm-1, 1730 cm-1, and 1611 cm-1 in TE could be detected in the spectrum of TE-SLNs, 352 
indicating the successful encapsulation of TE in the SLNs structure. It is also worth to mention 353 
that these absorption peaks in the spectrum of TE-SLNs have not been shifted significantly, which 354 
indicates the compatibility of the TE-SLNs components. However, there has been no significant 355 
interaction between them. In other words, the samples have been actually compatible. The main 356 
peaks of each component in the formulation of TE-SLNs are as follows: BW: 2916 cm-1 (-CH2-, 357 
asymmetric stretching), 2849 cm-1 (-CH2-, symmetric stretching), 1738 cm
-1 (C = O, stretching), 358 
1466 cm-1 (-CH2-, bending), and 1167 cm




stretching), 2920 cm-1 (-CH2-, asymmetric stretching), 2857 cm
-1 (-CH2-, symmetric stretching), 360 
1738 cm-1 (C=O, stretching). Tween 80: 3494 cm-1 (O-H, stretching), 2912 cm-1 (-CH2-, 361 
asymmetric stretching), 2857 cm-1 (-CH2-, symmetric stretching), 1738 cm
-1 (C=O, stretching). 362 
TE: 2927 cm-1 (-CH2-, asymmetric stretching), 2857 cm
-1 (-CH2-, symmetric stretching), 1730 cm
1 363 
(ester C=O, stretching), 1674 cm-1 (ketone C=O, stretching), 1611 cm-1 (conjugated C=C, 364 
stretching), 1171 cm-1 (C-O, stretching). 365 
 366 
 367 
3.2.2. Diff erential scanning calorimetry (DSC) 368 
As defined in the research protocol, the thermal characterization of NPs has been accomplished by 369 
DSC analyses to determine modifications in the crystalline state of the elements after medicine 370 
encapsulation. Accordingly, Fig. 2 presents the DSC thermograms of TE, BW, and TE-SLNs. 371 
According to the results, DSC thermograms of TE and BW experienced endothermic peaks at 39.4 372 
°C and 61 °C respectively, which corresponds to the respective melting point. These values are 373 
compatible with the values reported in the literature with a slight difference (37-38 °C for TE) [59] 374 
and (61.8 °C for BW) [60]. Thus, it could be concluded that the disappearance of the characteristic 375 
endothermic peak of TE near its melting point (39.4 °C) in the TE-SLNs thermogram could be 376 
related to either molecular dispersion of TE or the formation of TE-enriched core into the BW 377 
matrix. It could also be assumed that TE would be dissolved in an amorphous state in the molten 378 
beeswax during loading [61, 62]. Some researchers believe that this may inhibit TE crystallization 379 
in the process of nanoparticle preparation [31, 63]. 380 
 381 




The crystallite structure of the SLNs has been investigated to analyze the XRD diffraction patterns 383 
of TE, TE-SLNs and BW (Fig. 3). The XRD patterns of TE displayed characteristic peaks at 2θ 384 
corresponding to 5.33◦, 7.14◦, 7.97◦, 9.68◦, 11.26◦, 13.75◦, 14.81◦, 17.43◦, 18.48◦, and 19.37◦ [64]. 385 
Other studies demonstrated that the pattern of BW exhibited peaks at 2θ: 19.75◦, 21.60◦, 23.94◦, 386 
40.50◦, and 53.07◦ which are consistent with the orthorhombic crystal structure in beeswax [55, 65, 387 
66]. Moreover, the XRD patterns corresponding to the NPs formulation displayed the peaks 388 
corresponding to BW (2θ: 19.61◦, 21.52◦, 23.86◦, and 40.26◦). In addition, the disappearance of TE 389 
peaks and slight broadening of the TE-SLNs patterns indicated that testosterone enanthate in an 390 
amorphous state has been molecularly dispersed into the lipid phase [63] that is in agreement with 391 
results of DSC studies.  392 
 393 
3.2.4. TEM analysis 394 
TEM images of the TE-SLNs revealed that the nanoparticles are approximately in a uniform 395 
spherical shape with average sizes of 50 to 100 nm (Fig. 4). As can be seen, no sign of aggregation 396 
has been observed in the images so that the particle size has been under 100 nm. This result could 397 
be suggested because DLS provides intensity-based hydrodynamic diameters and mean of particle 398 
sizes, while TEM works on dry samples under ultra-high vacuum conditions [67]. In other words, 399 
the light scattering method actually evaluates the particle hydrodynamic radius that includes both 400 
particle size and the associated layers of the solvent on it. Moreover, these kinds of measurements 401 
are dynamic and highly dependent on the particle aggregation or dispersion behaviors in the 402 
solution [68]. 403 
 404 




In order to investigate the safety of the prepared SLNs, different concentrations of TE-SLNs 406 
containing 10 to 100 µg/ml of TE have been examined with different amounts of surfactants (ratio 407 
of span 80: tween 80, 1:2) on the Human gingival fibroblast cells (HGF3-PI53) for 24 h and 48 h. 408 
The results illustrated lower cell viability for the drug-free SLNs compared to the controls (P<0.05) 409 
(Fig. 5). It should be mentioned that the toxicity observed in the drug-free SLNs could not be 410 
related to the nature of the lipids, while it could be dependent on the characteristics of the 411 
surfactants [69] or may be related to the controlled release of TE in the culture medium. However, 412 
TE-SLNs at various TE concentrations (10, 25, 50, and 100 µg/ml) showed no cytotoxicity toward 413 
normal cells, suggesting that the SLNs cytotoxicity loaded with the lipophilic TE is greatly 414 
reduced. The lack of toxicity of TE-SLNs at different TE concentrations (with cell viability near 415 
100 %) compared with the drug-free SLNs (with cell viability about 72 %) could be resulted from 416 
binding surfactants to the SLNs surface, which led to a reduction in the surfactants cytotoxicity 417 
[70]. In other words, if the surfactants are bounded to the SLNs surface, their toxicity reduces 418 
compared to when they are free [69]. 419 
 420 
3.4. In vitro percutaneous absorption study 421 
It has been found that in vitro permeation study can be used for evaluating the skin permeation 422 
abilities of different systems. Thus, this examination was employed to analyze the percutaneous 423 
permeation profile of TE-SLNs. As reported in previous studies, water-insoluble compounds may 424 
not be able to penetrate into the excised skin and get into the aqueous receptor fluid in vitro [33]. 425 
However, for testosterone enanthate that is a water-insoluble drug (< 0.5 mg/ml) in a 426 
hydroalcoholic mixture (absolute ethanol/water, 70:30) was added into the Franz cell receptor 427 
compartment [52]. Since all prepared formulations were in nanosized range, the results indicate 428 




sizes was used, while studies have shown that encapsulation efficiency is the determining factor 430 
in skin absorption. As can be seen in Fig. 6, studies of the testosterone enanthate skin permeation 431 
in Y-axis revealed that the mean cumulative TE permeated amounts from the optimized TE-SLNs 432 
and TE-oleic acid solution after 24 h are 110.61±17.70 and 34.6±4.57 µg/cm2, respectively. Also, 433 
based on the Z-axis of this figure, the mean cumulative TE permeated percentages from these two 434 
formulations were 1.2±0.04 and 0.06±0.008 %, respectively. Thus, the permeation of TE-SLNs 435 
was higher than the oily solution of TE in oleic acid (P< 0.0001) at each time intervals of detection, 436 
indicating the enhanced penetration of TE-SLNs through rat skin. Factors related to enhanced skin 437 
permeation by TE-SLNs are assumed to include, the solubility of the drug, small particle size, 438 
large surface area, occlusive effect and presence of permeation enhancer, as reported in the 439 
literature for similar studies [71, 72]. Mechanistically, the solvation of lipophilic TE in SLNs rather 440 
than in water causes the concentration gradient towards the skin as observed for similar lipophilic 441 
drugs [73]. In addition, it is believed that nanoparticulate systems with small particle sizes have 442 
better chances to be in close contact with the stratum corneum (SC), thus, to adhere and penetrate 443 
into the skin to transport the drug in a controlled manner [74]. Furthermore, it is known that the 444 
SLNs exert an occlusive effect by forming films of dense-packed spheres on the surface of the 445 
skin, leading to increase skin hydration [71, 75]. These assumptions are consistent with those 446 
reported for similar studies. For example, Kelidari et al. explained that the spironolactone-SLNs 447 
exhibit a significant enhancement in the accumulative uptake of spironolactone through the skin 448 
onto the dispersion form of spironolactone [24]. Further, Guo et al. claimed that ivermectin-loaded 449 
SLNs formulations result in higher ivermectin penetration through the rat skin in comparison with 450 
the ivermectin suspension [31]. Finally, poor percutaneous absorption of the TE in the oleic acid 451 




suitable formulations of TE-SLNs would be regarded as the potential and efficient carriers for 453 
topical application of testosterone enanthate. 454 
 455 
4. CONCLUSION 456 
The present study successfully incorporated testosterone enanthate, which is a lipophilic drug, into 457 
a mixture of beeswax and surfactants to create a testosterone enanthate loaded solid lipid 458 
nanoparticles for transdermal delivery. The solid-state analysis of TE-SLNs indicated that 459 
testosterone enanthate dispersed into the lipid matrix in an amorphous form without any chemical 460 
interaction with average particle size, polydispersity index, zeta potential and encapsulation 461 
efficiency of 87.66± 1.52 nm, 0.317± 0.006, -23.06± 0.50 mV and 44.71± 1.14 %, respectively. In 462 
addition, in this examination, every significant visual change such as sedimentation, creaming and 463 
coalescence properties, as well as every alternation in the polydispersity index, particle size, zeta 464 
potential, and encapsulation efficiency for 90 days was recorded. According to the results, no 465 
considerable difference was observed. Furthermore, in vitro cytotoxicity study exhibited that the 466 
optimized testosterone enanthate loaded solid lipid nanoparticles have not been toxic due to an 467 
increased percentage of cell viability up to 100 %. Thus, this approach can be considered as a 468 
suitable alternative for the transdermal delivery of testosterone enanthate. Finally, it has been 469 
concluded that solid lipid nanoparticles are not only a promising carrier for topical delivery of 470 
testosterone enanthate, but also they could be applied as a carrier for the drugs that could cause 471 
gastrointestinal problems. 472 
 473 
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Table 1. Effect of HLB on particle size, polydispersity index, zeta potential and encapsulation efficiency 693 






























































































































































































Fig 5. Cell viability of drug-free SLNs and different concentrations of TE-SLNs. Data are expressed as 747 
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Fig 6. permeated TE from TE-oleic acid and TE-SLNs across rat skin. Data were expressed as the Mean ± 753 
SD. 754 
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